Cytabin IV Infusion 1000 mg/vial is an anti-cancer chemotherapy drug. It is classified as an antimetabolite, as it works by preventing cells from producing new DNA strands that are needed for reproduction and division. It is most commonly used in the treatment of acute leukemias. It is a cytotoxic drug, meaning it begins to kill rapidly dividing cells such as cancer cells. While it is used to treat cancer, it could also potentially be used to treat other conditions that involve abnormal divisions, such as skin disorders or viral infections.
Cytabin IV Infusion 1000 mg/vial is primarily used to treat acute leukemias, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It can also be used to treat certain types of myelodysplastic syndromes, non-Hodgkin’s lymphoma, and other types of cancer. Cytabin IV Infusion 1000 mg/vial may also be used in other cases where cells are rapidly dividing, such as viral infections or skin disorders.
| Brand Name | Cytabin |
|---|---|
| Type | IV Infusion |
| Weight | 1000 mg/vial |
| Generic | Cytarabine |
| Manufacturer | Beacon Pharmaceuticals PLC |
| Available in | English বাংলা |
Cytabin IV Infusion 1000 mg/vial works by inhibiting the enzymes that are responsible for producing DNA strands, which are required for cells to replicate and divide. This prevents the cancer cells from dividing, which eventually leads to their death. Cytabin IV Infusion 1000 mg/vial is also able to penetrate into healthy cells, which allows it to treat multiple types of cancer and other conditions.
The effectiveness of cytarabine depends largely on its dosage and the type of cancer being treated. In most cases, it takes several weeks for the drug to start having an effect. In some cases, it may take up to several months for the drug to reach its full potential.
Cytabin IV Infusion 1000 mg/vial is mainly metabolized in the liver and absorbed by small intestine. There is no significant difference in absorption between oral and intravenous administration.
Cytabin IV Infusion 1000 mg/vial is eliminated from the body primarily through urine. About 15-25% of the drug is metabolized by the liver and eliminated through feces.
The dosage of cytarabine depends on the type of cancer being treated, the severity of the condition, and weight of the patient. Generally, the recommended dosage for adults is 10-30 mg/m2 daily, divided into two dose administrations over 24 hours.
Cytabin IV Infusion 1000 mg/vial is available in both oral and intravenous forms. It can be taken orally or injected intravenously. Generally, the intravenous form is preferred over the oral form, as it is more potent and has a faster onset of action.
Common side effects of cytarabine include nausea, vomiting, diarrhea, hair loss, fatigue, and headache. More serious side effects include bone marrow suppression, increased risk of infection, and anemia.
High doses of cytarabine can be toxic, potentially causing serious side effects. These side effects can include anemia, kidney failure, abnormal heart rhythms, and seizures. If any of these symptoms occur, the patient should seek medical attention immediately.
Patients with a history of kidney or liver disease, anemia, or bleeding disorders should be monitored closely while taking cytarabine. Patients should also be monitored for signs of infection, as cytarabine can lower the body’s count of white blood cells. As with any medication, patients should seek medical attention if any unusual symptoms occur.
Cytabin IV Infusion 1000 mg/vial can interact with many medications and cause serious side effects. It should not be taken with any medications that lowers the body’s counts of white blood cells, such as antifungals or antibiotics. Patients should always inform their healthcare provider about all medications they are taking before taking cytarabine.
Cytabin IV Infusion 1000 mg/vial can interact with other diseases or medical conditions and cause serious side effects. Patients with kidney or liver diseases, anemia, or bleeding disorders should be monitored closely while taking cytarabine. Patients with any type of infection should also be monitored, as cytarabine can lower the body’s white blood cell count.
Cytabin IV Infusion 1000 mg/vial should not be taken with any medications that lowers the body’s white blood cell counts, such as antibiotics or antifungals. It should also not be taken with warfarin or other blood thinners, as this may increase the risk of bleeding. Patients should always inform their healthcare provider of all medications they are taking before taking cytarabine.
Cytabin IV Infusion 1000 mg/vial should not be taken with grapefruit juice as it can increase the risk of side effects. Patients should also avoid caffeine, alcohol, and any other substances that can interfere with the metabolism of the drug. If any unusual symptoms occur, the patient should seek medical attention.
Cytabin IV Infusion 1000 mg/vial should not be taken during pregnancy, as there is potential for fetal damage. Women who are pregnant or may become pregnant should inform their healthcare provider before taking cytarabine.
Cytabin IV Infusion 1000 mg/vial, as a chemotherapeutic agent, is not approved for use in breast-feeding women. It could potentially pass through breast milk and cause serious side effects to a nursing baby.
Any overdose of cytarabine should be treated as a medical emergency. Symptoms of an overdose may include headache, fever, chills, and/or confusion. A patient should seek medical attention immediately if any unusual symptoms occur.
Cytabin IV Infusion 1000 mg/vial should not be taken in patients with serious kidney or liver disease, anemia, or bleeding disorders, as it may exacerbate symptoms and cause serious side effects. Patients should also avoid taking cytarabine if they are pregnant or breastfeeding.
Cytabin IV Infusion 1000 mg/vial should be taken exactly as prescribed by a healthcare provider. The dosage will depend on the type of cancer being treated, the severity of the condition, and weight of the patient. The drug should not be taken with any medications that lowers the white blood cell counts, such as antibiotics or antifungals. Patients should also avoid grapefruit juice while taking cytarabine.
Cytabin IV Infusion 1000 mg/vial should be stored at room temperature, away from heat and moisture. It should also be kept away from children and pets.
The volume of distribution of cytarabine is 2.2-2.9 L/kg.
The half life of cytarabine is 1-2 hours.
The urinary clearance of cytarabine is 0.45-0.65 ml/min/kg.
See in details version Cytabin IV Infusion 1000 mg/vial also Cytabin IV Infusion 1000 mg/vial in bangla